It was announced today (October 31), that the US Food and Drug Administration (FDA) has granted permission to proceed with clinical investigations of small molecule treatment, roginolisib.
The escalation of a drug targeting tumors, by releasing active chemotherapy into the disease tissue, has had ‘remarkable’ results and also shown a reduction in side-effects.
Artificial intelligence (AI) biotech company, Owkin, has invested $50million in a project that will use spatial omics, a set of cutting-edge technologies that offer unprecedented information on the structure of tumors.